Loading…
The agreement includes the issuance of DWTX common stock and preferred stock.
Dogwood Therapeutics, Inc. (DWTX) announced on September 29, 2025, that it has secured an exclusive worldwide, royalty-free license to develop and commercialize SP16 as a treatment for cancer-related pain. The agreement involves the issuance of 382,034 shares of DWTX common stock and 179.1878 shares of a new series of non-voting convertible preferred stock, representing 7.31% of the Company’s common stock on a fully diluted basis.
The license allows Dogwood Therapeutics to utilize SP16 for the specified indication, with the stock issuance serving as part of the consideration for the agreement. The new series of preferred stock is non-voting and convertible, adding to the equity structure of the company.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.